Open Access

MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1

Retraction in: /10.3892/etm.2021.10628

  • Authors:
    • Quanqing Zou
    • Qianli Tang
    • Yinhua Pan
    • Xuedi Wang
    • Xiaofeng Dong
    • Zhongxiao Liang
    • Dong Huang
  • View Affiliations

  • Published online on: June 13, 2017     https://doi.org/10.3892/etm.2017.4590
  • Pages: 1009-1016
  • Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRs), which are a class of small non-coding RNAs, are key regulators of gene expression via induction of translational repression or mRNA degradation. However, the molecular mechanism of miR‑22 underlying the malignant progression of breast cancer, remains to be elucidated. The present study aimed to explore the regulatory mechanism of miR‑22 in breast cancer cell growth and metastasis. Reverse transcription‑quantitative polymerase chain reaction data revealed that miR‑22 was significantly downregulated in breast cancer tissues, compared with adjacent non‑tumor tissues. Furthermore, the miR‑22 levels were further decreased in stage III‑IV, compared with stage I‑II breast cancer. In addition, low miR‑22 levels were significantly associated with the poor differentiation, metastasis and advanced clinical stages of breast cancer. Sirtuin1 (SIRT1) was demonstrated to act as a direct target gene of miR‑22 and its protein expression negatively regulated by miR‑22 in the MCF‑7 breast cancer cell line. Furthermore, SIRT1 expression levels were significantly upregulated in breast cancer tissues, compared with adjacent non‑tumor tissues. SIRT1 levels were observed to be increased in stage III‑IV when compared with stage I‑II breast cancer. miR‑22 overexpression decreased the proliferation, migration and invasion of MCF‑7 cells, whereas overexpression of SIRT1 eliminated the suppressive effects of the miR‑22 overexpression on the malignant phenotype of MCF‑7 cells. The results of the present study therefore suggested that miR‑22 demonstrated suppressive effects on breast cancer growth and metastasis via targeting SIRT1, and thus the miR‑22/SIRT1 axis may be used as a novel and potential therapeutic target for breast cancer in the future.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zou Q, Tang Q, Pan Y, Wang X, Dong X, Liang Z and Huang D: MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1 Retraction in /10.3892/etm.2021.10628. Exp Ther Med 14: 1009-1016, 2017.
APA
Zou, Q., Tang, Q., Pan, Y., Wang, X., Dong, X., Liang, Z., & Huang, D. (2017). MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1 Retraction in /10.3892/etm.2021.10628. Experimental and Therapeutic Medicine, 14, 1009-1016. https://doi.org/10.3892/etm.2017.4590
MLA
Zou, Q., Tang, Q., Pan, Y., Wang, X., Dong, X., Liang, Z., Huang, D."MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1 Retraction in /10.3892/etm.2021.10628". Experimental and Therapeutic Medicine 14.2 (2017): 1009-1016.
Chicago
Zou, Q., Tang, Q., Pan, Y., Wang, X., Dong, X., Liang, Z., Huang, D."MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1 Retraction in /10.3892/etm.2021.10628". Experimental and Therapeutic Medicine 14, no. 2 (2017): 1009-1016. https://doi.org/10.3892/etm.2017.4590